HAPLN1 and gastric cancer: We then performed the validation studies to further confirm that the serum HAPLN1 levels in gastric cancer patients were much higher than those in healthy controls (836.4 ± 60.88 ng/ml vs 606.8 ± 73.37 ng/ml, P < 0.001) (Fig. 2A).